Sanofi and Cheplapharm announce mature medicines partnership

Sanofi and Cheplapharm announced on September 14, 2026 plans for a new strategic partnership focused on mature medicines. Under the proposed deal, Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide.¹ In exchange, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014.¹

The three sites involved would move to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees).¹ The companies said existing employment arrangements and collective agreements would be maintained for the affected teams.¹

Among the medicines changing hands is Lovenox/Clexane (enoxaparin), excluding sales in the US.¹ Cheplapharm's co-CEOs noted the deal brings them the expertise and manufacturing capabilities required to produce a flagship product, Lovenox/Clexane.¹

On timing, the companies said the commercial handover of the medicines is targeted to start in early 2027, with site transfers to follow, pending consultations with employee representatives, regulatory clearances, and other closing conditions. The transaction is expected to be fully completed by the third quarter of 2027.¹

Sanofi said the proposed transaction is not expected to have any impact on the company's financial guidance for 2026,¹ and added that additional financial details are expected to be provided at a later stage.¹

Cheplapharm, a Germany-based family-owned pharmaceutical company, said it has invested more than 6.2 billion euros since its founding, acquired close to 100 products since 2015, and now holds 3,440 marketing authorizations spanning 160 countries.¹